We and others have previously demonstrated that selective pharmacological inhibition of DNA-PK is able to synergistically enhance the anti-tumor activity of anthracyclines, including doxorubicin, in a large variety of cancer cell lines in vitro [14] and xenograft models in vivo. This evidence concerns the gene PRKDC and neoplasm.